Protocol Ledger

NCT07061080 · Phase II · TERMINATED

Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab

Interventional Phase II clinical trial protocol NCT07061080 sponsored by Grupo Espanol de Tumores Neuroendocrinos in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-12-18 Enrollment: 1 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT07061080
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)1 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07061080
Protocol FieldVerified Registry Value
NCT IdentifierNCT07061080
Consolidated Lead SponsorGrupo Espanol de Tumores Neuroendocrinos
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment1 participants (ACTUAL)
Registered Start Date2025-12-18
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07061080
Hospital Research SiteLocationSite Profile
Centre Oscar LambretLille, FranceOpen Hospital Dossier ->
Gustave RoussyVillejuif, FranceOpen Hospital Dossier ->
Hospital Universitario Marqués de ValdecillaSantander, SpainOpen Hospital Dossier ->
Hospital General Universitario Gregorio MarañónMadrid, SpainOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI